Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Sunitinib,SUN1001,2021,USA,MDV,350,62,35,65,27.5,42,88,12,15,25,30,30,60,20,15,5,20,30,35,18,7,3,9,5,10,25,30,Gemcitabine + Cisplatin,Docetaxel + Carboplatin,5-FU + Leucovorin,Capecitabine,0,0,0,20,45,55,15,40,45,60,2
Sunitinib,SUN1002,2022,Canada,Claim Database,420,68,38,62,28.1,38,85,15,12,28,32,28,58,22,14,6,18,32,33,20,8,4,10,6,12,28,32,Gemcitabine + Cisplatin,Docetaxel + Carboplatin,5-FU + Leucovorin,Capecitabine,0,0,0,22,48,58,12,38,50,65,2.5
Sunitinib,SUN1003,2023,UK,MDV,280,70,40,60,29.0,35,82,18,10,30,35,25,55,25,13,7,15,35,38,22,9,5,11,7,15,30,35,Gemcitabine + Cisplatin,Docetaxel + Carboplatin,5-FU + Leucovorin,Capecitabine,0,0,0,25,50,60,10,35,55,70,3
Sunitinib,SUN1004,2023,Germany,Claim Database,480,65,33,67,26.8,45,90,10,18,22,28,32,62,18,13,7,22,28,32,16,6,2,8,4,8,22,28,Gemcitabine + Cisplatin,Docetaxel + Carboplatin,5-FU + Leucovorin,Capecitabine,0,0,0,18,42,52,17,42,41,58,1.8
Sunitinib,SUN1005,2022,Japan,MDV,300,72,28,72,24.5,50,78,20,20,20,30,30,50,25,15,10,25,25,30,25,10,6,12,8,20,35,40,Gemcitabine + Cisplatin,Docetaxel + Carboplatin,5-FU + Leucovorin,Capecitabine,0,0,0,30,55,65,8,30,62,75,3.5
